David D. O'Toole

David D. O'Toole (finance chief) discloses dealings in 2 companies, chiefly AVITA Medical, Inc. and Opiant Pharmaceuticals, Inc. Over a trading history stretching from 16 August 2021 to 12 June 2026, the count stands at 38 filings.

Both buying and selling appear: 24 purchases worth €264k, against 5 sales worth €69k. On balance, insiders were net buyers of €195k. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Besides market trades, the filings include 8 share grants. Since January 2026: 4 purchases and no sales on the market.

Half of the purchases are above €10k and half below. On 4 out of 24 purchases, another insider of the same company was buying within the same 30 days. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase. Looking at 13 purchases old enough to measure, the stock rose over the following 90 days in 31% of cases; the median change was -12.3%. They describe history only and say nothing certain about the share price ahead.

The record was last updated on 24 August 2026 with an open-market purchase (€6,859) in AVITA Medical, Inc. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. The legal deadline for a Form 4 is two business days after the transaction. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.